CO4950556A1 - QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM. - Google Patents

QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM.

Info

Publication number
CO4950556A1
CO4950556A1 CO98037149A CO98037149A CO4950556A1 CO 4950556 A1 CO4950556 A1 CO 4950556A1 CO 98037149 A CO98037149 A CO 98037149A CO 98037149 A CO98037149 A CO 98037149A CO 4950556 A1 CO4950556 A1 CO 4950556A1
Authority
CO
Colombia
Prior art keywords
group
compositions
contain
ncn
quinoline derivatives
Prior art date
Application number
CO98037149A
Other languages
Spanish (es)
Inventor
Rajeev S Bhide
Charles Z Ding
John T Hunt
Kim Soong-Hoom
Leftheris Katerina
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO4950556A1 publication Critical patent/CO4950556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula I o IIcaracterizado porque:1, m, r, s y t son 0 ó 1;n es 0, 1 ó 2;y se selecciona del grupo que consiste de CHR12 , SO2 , SO3 , CO , CO2 , O, NR13 , SO2 NR14 , CONR15 , C(NCN), C(NCN)NR16 , NR17 CO, NR18 SO2 , CONR19 NR20 , SO2 NR21 NR22 , S(O)(NR23 ), S(NR24 ) (NR25 ), o sin Y;Z se selecciona del grupo que consiste de CR12 , S, SO, SO2 , SO3 , CO, CO2 , O, NR13 , SO2 NR14 , CONR15 , NR26 NR27 , ONR28 , NR29 O, NR30 SO2 NR31 , NR32 SO2 , NR33 C(NCN), NR34 C(NCN)NR35 , NR36 CO, NR37 CONR38 , NR39 CO2 , OCONR40 , S(O)(NR41 ), S(NR42 ) NR43 ) o CHR12 ; o sin Z;R7 , R8 se seleccionan del grupo que consiste de hidrógeno halo, nitro, ciano y U-R44 ;U se selecciona del grupo que consiste de S, O, NR45 , CO, SO, SO2 , CO2 , NR46 CO2 , NR47 CONR48 , NR49 SO2 , NR50 SO2 NR51 , SO2 NR52 , NR53 CO, CONR54 , PO2 R55 y PO3 R56 o sin U;R9 , R10 , R12 , R13 , R14 , R15 , R16 , R17 , R18 , R19 , R20 , R21 , R22 , R23 , R24 , R25 ,R26 , R27 , R28 , R29 , R30 , R31 , R32 , R33 , R34 , R35 , R36 , R37 , R38 , R39 , R40 , R41 , R42 , R43 , R44 , R45 , R46 , R47 , R48 , R49 , R50 , R51 , R52 , R53 , R54 , R55 , R56 , R57 , R58 , R59 , se seleccionan del grupo que consiste de hidrógeno, alquilo inferior, arilo, heterociclo, alquilo sustituido o arilo;R11 y R44 se seleccionan del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, aralquilo, cicloalquilo, arilo,...A compound of formula I or II characterized in that: 1, m, r, s and t are 0 or 1; n is 0, 1 or 2; and is selected from the group consisting of CHR12, SO2, SO3, CO, CO2, O, NR13, SO2 NR14, CONR15, C (NCN), C (NCN) NR16, NR17 CO, NR18 SO2, CONR19 NR20, SO2 NR21 NR22, S (O) (NR23), S (NR24) (NR25), or without Y ; Z is selected from the group consisting of CR12, S, SO, SO2, SO3, CO, CO2, O, NR13, SO2 NR14, CONR15, NR26 NR27, ONR28, NR29 O, NR30 SO2 NR31, NR32 SO2, NR33 C ( NCN), NR34 C (NCN) NR35, NR36 CO, NR37 CONR38, NR39 CO2, OCONR40, S (O) (NR41), S (NR42) NR43) or CHR12; or without Z; R7, R8 are selected from the group consisting of halo, nitro, cyano and U-R44 hydrogen; U is selected from the group consisting of S, O, NR45, CO, SO, SO2, CO2, NR46 CO2, NR47 CONR48, NR49 SO2, NR50 SO2 NR51, SO2 NR52, NR53 CO, CONR54, PO2 R55 and PO3 R56 or without U; R9, R10, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 , R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46 , R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, are selected from the group consisting of hydrogen, lower alkyl, aryl, heterocycle, substituted alkyl or aryl; R11 and R44 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, ...

CO98037149A 1997-07-02 1998-07-01 QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM. CO4950556A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5159497P 1997-07-02 1997-07-02

Publications (1)

Publication Number Publication Date
CO4950556A1 true CO4950556A1 (en) 2000-09-01

Family

ID=21972255

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98037149A CO4950556A1 (en) 1997-07-02 1998-07-01 QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM.

Country Status (24)

Country Link
US (2) US6387926B1 (en)
EP (1) EP0994856A4 (en)
JP (1) JP2002507989A (en)
KR (1) KR100385941B1 (en)
CN (1) CN1261880A (en)
AR (1) AR016304A1 (en)
AU (1) AU734721B2 (en)
BR (1) BR9810465A (en)
CA (1) CA2294530A1 (en)
CO (1) CO4950556A1 (en)
HU (1) HUP0004148A3 (en)
ID (1) ID24076A (en)
IL (1) IL133470A0 (en)
MY (1) MY117961A (en)
NO (1) NO316117B1 (en)
NZ (1) NZ501293A (en)
PE (1) PE86599A1 (en)
PL (1) PL337697A1 (en)
RU (1) RU2211838C2 (en)
TR (1) TR199903331T2 (en)
TW (1) TW527355B (en)
UY (1) UY25074A1 (en)
WO (1) WO1999001434A1 (en)
ZA (1) ZA985778B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340100A1 (en) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
AU754204B2 (en) * 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
MXPA02006474A (en) * 1999-12-28 2002-11-29 Eisai Co Ltd Heterocyclic compounds having sulfonamide groups.
GB0023915D0 (en) * 2000-09-29 2000-11-15 Inst Of Ophthalmology Treatment of neuroinflammatory disease
DK1339407T3 (en) * 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
FR2819510B1 (en) * 2001-01-18 2003-10-31 Servier Lab NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2819512B1 (en) * 2001-01-18 2003-02-21 Servier Lab NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2825705B1 (en) * 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
FR2844273B1 (en) 2002-09-05 2008-04-04 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS.
CA2470365C (en) * 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as cannabinoid receptor modulators
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Methods for the treatment of synucleinopathies
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
KR101589551B1 (en) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
CA2634598A1 (en) * 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
ES2531190T3 (en) * 2006-03-06 2015-03-11 Japan Tobacco Inc Method to produce a 4-oxoquinoline compound
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
JP2010510184A (en) * 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー Substituted 4-imidazoles
NZ580802A (en) * 2007-05-10 2012-09-28 Albany Molecular Res Inc Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
FR2920773B1 (en) * 2007-09-11 2009-10-23 Servier Lab 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
CN103864765B (en) * 2014-03-05 2016-02-10 天津药物研究院 Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
ES2926579T3 (en) 2016-05-05 2022-10-27 Laurus Labs Ltd Process for the preparation of intermediate compounds useful in the preparation of inhibitors of the Hepatitis C virus (HCV)
WO2017213210A1 (en) * 2016-06-10 2017-12-14 武田薬品工業株式会社 Heterocyclic compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
JPS5852256A (en) * 1981-09-24 1983-03-28 Nippon Nohyaku Co Ltd Substituted or unsubstituted fatty acid amide derivative and its salt
JPS60222479A (en) * 1984-04-20 1985-11-07 Nippon Tokushu Noyaku Seizo Kk Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, their production and herbicide and fungicide therefrom
US4576957A (en) 1984-07-05 1986-03-18 American Cyanamid Company N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas
JPS6160682A (en) * 1984-08-30 1986-03-28 Nippon Tokushu Noyaku Seizo Kk Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, its production, herbicide, agricultural and horticultural fungicide
JPS6168487A (en) * 1984-09-12 1986-04-08 Sumitomo Chem Co Ltd Carbamoylazole derivative, its production, and herbicide comprising it as active ingredient
US5017584A (en) 1984-12-20 1991-05-21 Sterling Drug Inc. Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
JPS61227506A (en) * 1985-04-01 1986-10-09 Nippon Tokushu Noyaku Seizo Kk Carbamoylimidazole, intermediate and, production thereof and herbicide, agricultural and horticultural fungicide
JPS61280408A (en) * 1985-06-03 1986-12-11 Sumitomo Chem Co Ltd Tobacco sucker inhibitor
JPS63270678A (en) * 1987-04-30 1988-11-08 Mitsui Petrochem Ind Ltd Novel nitrogen-containing compound
JP2652249B2 (en) 1989-08-22 1997-09-10 進 根本 Key knob cover
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
EP0485890A3 (en) * 1990-11-16 1992-07-08 Hoechst Aktiengesellschaft Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US5726197A (en) 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5523317A (en) 1993-07-05 1996-06-04 Nippon Chemiphar Co., Ltd. Method of reducing blood pressure
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
HU217841B (en) 1993-12-17 2000-04-28 The Procter & Gamble Co. 6-(2-imidazolidinylidene-amino)quinoline derivatives, and pharmaceutical compositions containing them
RU95104898A (en) * 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Imedazole containing inhibitors of ferneside proteintansferase, and method of treatment diseases related therewith
US5607939A (en) 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
TW436484B (en) 1996-04-24 2001-05-28 Dev Center Biotechnology 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof
WO1998002432A1 (en) 1996-07-16 1998-01-22 Takeda Chemical Industries, Ltd. Bicyclic compounds for controlling micturition
UA60311C2 (en) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists

Also Published As

Publication number Publication date
PL337697A1 (en) 2000-08-28
US6387926B1 (en) 2002-05-14
HUP0004148A3 (en) 2002-09-30
NZ501293A (en) 2001-10-26
UY25074A1 (en) 2000-12-29
KR100385941B1 (en) 2003-06-09
BR9810465A (en) 2002-04-16
TR199903331T2 (en) 2000-06-21
EP0994856A1 (en) 2000-04-26
JP2002507989A (en) 2002-03-12
NO996571L (en) 2000-02-23
CA2294530A1 (en) 1999-01-14
AU7971998A (en) 1999-01-25
HUP0004148A2 (en) 2001-10-28
PE86599A1 (en) 1999-11-28
NO316117B1 (en) 2003-12-15
US6602883B1 (en) 2003-08-05
KR20010014258A (en) 2001-02-26
ZA985778B (en) 2000-01-20
TW527355B (en) 2003-04-11
ID24076A (en) 2000-07-06
NO996571D0 (en) 1999-12-30
WO1999001434A1 (en) 1999-01-14
EP0994856A4 (en) 2000-12-06
CN1261880A (en) 2000-08-02
IL133470A0 (en) 2001-04-30
RU2211838C2 (en) 2003-09-10
AU734721B2 (en) 2001-06-21
AR016304A1 (en) 2001-07-04
MY117961A (en) 2004-08-30

Similar Documents

Publication Publication Date Title
CO4950556A1 (en) QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM.
AR015774A1 (en) EPOTILONE DERIVATIVES 12,13-MODIFIED AND ITS SALTS
AR045761A1 (en) DERIVATIVES OF 2-PIRIDONA AS INHIBITORS OF ELASTASA DE NEUTROFILOS
AR030432A1 (en) USE OF QUINAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT TO BE USED IN THE INHIBITION OF AURORA QUINASA2, RELATED COMPOUNDS, AND PHARMACEUTICAL COMPOSITION.
TR199903270T2 (en) Omeprazole sodium salt.
AR045691A1 (en) HETEROARILAMIDE DERIVATIVES AS P2X7 ANTAGONIST RECEIVERS AND THEIR USES
BG62615B1 (en) (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase
HK1028032A1 (en) Pyridonecarboxylic acid derivatives or their salts, and antibacterial agent comprising the same as the active ingredient
NZ334125A (en) Quinoline derivatives inhibiting the effect of growth factors such as VEGF
PT96937A (en) (4-PIPERIDINYL) (DIHYDRO-BENZOFURAN OR DIHYDRO-2H-BENZOPYRAN) CARBOXAMIDE AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TR200201413T2 (en) Inhibitors of Factor Xa.
TR200600172T1 (en) Inhibitors of replication of respiratory system syncytial virus.
AR039564A1 (en) CARBONILAMINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETILASE, PHARMACEUTICAL COMPOSITIONS AND PROCESSES OF PREPARATION OF THE COMPOUND AND OF THE COMPOSITIONS CONTAINING IT
AR060042A1 (en) NANOPARTICLES UNDERSTANDING A PDGF RECEPTOR THYROSINE KINASE INHIBITOR
CO5190701A1 (en) TREATMENT OF COMBINATION WITH II-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF II-1
PL350123A1 (en) Tetrahydropyran derivatives and their use as therapeutic agents
TR200000414T2 (en) 2- (4-Aryl or heteroaryl-piperazin-1-ylmethyl) -1H-indole derivatives.
AR042733A1 (en) PIRIDINE DERIVATIVES USED AS INHIBITORS OF THE NA + / CA2 + EXCHANGE MECHANISM
NZ502180A (en) 6-Azauracil derivatives and their use as IL-5 inhibitors
ATE218538T1 (en) AZAHEXANE DERIVATIVES AS SUBSTRATISOSTERS OF RETROVIRAL ASPARTATE PROTEASES
MY127758A (en) Derivatives of homopiperidinyl substituted benzimidazole analogues
AR046770A1 (en) BENCIMIDAZOL 5- OR 6-SUBSTITUTED DERIVATIVES AS INHIBITORS OF THE REPLICATION OF RESPIRATORY SINCITIAL VIRUS
CO5221028A1 (en) FUNGICIDE MIXTING THAT INCLUDES DERIVATIVES OF ETER QUINOLINE AND CARBAMATES
DE60000234D1 (en) Indole compounds, their use in dyeing and making up keratin fibers, compositions containing them and dyeing processes
DK19787D0 (en) SUBSTITUTED AMIDS, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS